Why the study?
Does aspirin reduce vascular plasminogen activator activity in human subjects?
Population
13 human subjects
Comparison
Aspirin 650 mg/d for 2 days vs Baseline (before aspirin administration)
Design
Cohort
Authors
Loading...
Supports antifibrinolytic effect of aspirin on venous occlusion response; leaves open whether this affects cardiovascular outcomes.
Does aspirin reduce vascular plasminogen activator activity in human subjects?
Aspirin demonstrates a previously undescribed antifibrinolytic effect by inhibiting the rise in tissue-type plasminogen activator activity following venous occlusion.
Levin et al. (1984) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: